Bioengineered nanotechnology for nucleic acid delivery.

Nucleic Acids Nanotechnology Proteins Drug Delivery Systems Nanoparticles
Bioengineered nanotechnology Cell membrane-derived nanovesicle Exosome Nucleic acid delivery Protein nanocage Virus-like particle

Journal

Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 12 07 2023
revised: 15 10 2023
accepted: 21 10 2023
medline: 5 12 2023
pubmed: 26 10 2023
entrez: 25 10 2023
Statut: ppublish

Résumé

Nucleic acid-based therapy has emerged as a promising therapeutic approach for treating various diseases, such as genetic disorders, cancers, and viral infections. Diverse nucleic acid delivery systems have been reported, and some, including lipid nanoparticles, have exhibited clinical success. In parallel, bioengineered nucleic acid delivery nanocarriers have also gained significant attention due to their flexible functional design and excellent biocompatibility. In this review, we summarize recent advances in bioengineered nucleic acid delivery nanocarriers, focusing on exosomes, cell membrane-derived nanovesicles, protein nanocages, and virus-like particles. We highlight their unique features, advantages for nucleic acid delivery, and biomedical applications. Furthermore, we discuss the challenges that bioengineered nanocarriers face towards clinical translation and the possible avenues for their further development. This review ultimately underlines the potential of bioengineered nanotechnology for the advancement of nucleic acid therapy.

Identifiants

DOI: 10.1016/j.jconrel.2023.10.034 PMID: 37879440
pubmed: 37879440
pii: S0168-3659(23)00684-3
doi: 10.1016/j.jconrel.2023.10.034
pii:
doi:

Substances chimiques

Nucleic Acids 0
Proteins 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

124-141

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors stated that they have no competing interests.

Auteurs

Yang Zhang (Y)

State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, China; Center for Nanomedicine and Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Jing Luo (J)

Department of Urology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Xiran Gui (X)

State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, China.

Yating Zheng (Y)

State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, China.

Eric Schaar (E)

Center for Nanomedicine and Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Gang Liu (G)

State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, China. Electronic address: gangliu.cmitm@xmu.edu.cn.

Jinjun Shi (J)

Center for Nanomedicine and Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: jshi@bwh.harvard.edu.

Articles similaires

Exploring structural diversity across the protein universe with The Encyclopedia of Domains.

Andy M Lau, Nicola Bordin, Shaun M Kandathil et al.
1.00
Databases, Protein Protein Domains Protein Folding Proteins Deep Learning

Mathematical modeling of vancomycin release from Poly-L-Lactic Acid-Coated implants.

Papon Thamvasupong, Kwanchanok Viravaidya-Pasuwat
1.00
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation

Reprogramming cellular senescence in the tumor microenvironment augments cancer immunotherapy through multifunctional nanocrystals.

Zheng Wang, Yinglu Chen, Hui Fang et al.
1.00
Tumor Microenvironment Nanoparticles Immunotherapy Cellular Senescence Animals

Multifunctional hybrid films made from CoT3OTx4 and CoFeT2OT4 nanoparticles inside a poly 3-hydroxybutyrate matrix and study of their impact in methyl orange photodegradation.

Lan J Bernal-Sánchez, América R Vázquez-Olmos, Roberto Y Sato-Berrú et al.
1.00
Cobalt Azo Compounds Ferric Compounds Polyesters Photolysis

Classifications MeSH

questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › Bioengineered nanotechnology for nucleic acid delivery.
questionsmedicales.fr › Technologie, industrie et agriculture › Technologie › Miniaturisation › Nanotechnologie › Bioengineered nanotechnology for nucleic acid delivery.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Bioengineered nanotechnology for nucleic acid delivery.
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › Bioengineered nanotechnology for nucleic acid delivery.
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Nanostructures › Nanoparticules › Bioengineered nanotechnology for nucleic acid delivery.